skip to content
Sarilumab (Kevzara). Preview this item
ClosePreview this item
Checking...

Sarilumab (Kevzara).

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, May 2017.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
The objective of this report is to provide a systematic review of the beneficial and harmful effects of sarilumab for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs).
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Review
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1086619630
Description: 1 online resource (1 PDF file (xiii, 107 pages)) : illustrations.
Series Title: Common drug review clinical review report.
Other Titles: CDR clinical review report for Kevzara

Abstract:

The objective of this report is to provide a systematic review of the beneficial and harmful effects of sarilumab for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs).

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1086619630> # Sarilumab (Kevzara).
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
    library:oclcnum "1086619630" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8938423045#Topic/antibodies_monoclonal_humanized_therapeutic_use> ; # Antibodies, Monoclonal, Humanized--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8938423045#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8938423045#Topic/arthritis_rheumatoid_drug_therapy> ; # Arthritis, Rheumatoid--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/8938423045#Topic/antirheumatic_agents_adverse_effects> ; # Antirheumatic Agents--adverse effects
    schema:alternateName "CDR clinical review report for Kevzara" ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8938423045#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2017" ;
    schema:description "The objective of this report is to provide a systematic review of the beneficial and harmful effects of sarilumab for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs)."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8938423045> ;
    schema:genre "Review"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8938423045#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8938423045#Series/cadth_common_drug_review_clinical_review_report> ; # CADTH common drug review clinical review report
    schema:name "Sarilumab (Kevzara)."@en ;
    schema:productID "1086619630" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK534411/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1086619630> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8938423045#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8938423045#Series/cadth_common_drug_review_clinical_review_report> # CADTH common drug review clinical review report
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1086619630> ; # Sarilumab (Kevzara).
    schema:name "CADTH common drug review clinical review report" ;
    .

<http://experiment.worldcat.org/entity/work/data/8938423045#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1086619630> ; # Sarilumab (Kevzara).
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8938423045#Topic/antibodies_monoclonal_humanized_therapeutic_use> # Antibodies, Monoclonal, Humanized--therapeutic use
    a schema:Intangible ;
    schema:name "Antibodies, Monoclonal, Humanized--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8938423045#Topic/antirheumatic_agents_adverse_effects> # Antirheumatic Agents--adverse effects
    a schema:Intangible ;
    schema:name "Antirheumatic Agents--adverse effects"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8938423045#Topic/arthritis_rheumatoid_drug_therapy> # Arthritis, Rheumatoid--drug therapy
    a schema:Intangible ;
    schema:name "Arthritis, Rheumatoid--drug therapy"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.